Enhertu Success Stories: Inspiring Tales of Triumph in Cancer …
WEBRead about the incredible success stories of Enhertu, a groundbreaking cancer treatment, and learn how it is transforming the lives of patients. Explore real-life accounts of individuals who have experienced the life-changing benefits of Enhertu.
Enhertu Breast Cancer Drug Results in ‘Unheard-of’ Survival Rates
WEBJune 7, 2022. The patients had metastatic breast cancer that had been progressing despite rounds of harsh chemotherapy. But a treatment with a drug that targeted cancer cells with laserlike...
Enhertu demonstrated a median progression-free survival of 13.2 …
WEBJun 2, 2024 · With Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive and HER2-low metastatic breast cancer and are exploring its potential in earlier lines of treatment and in new breast cancer settings.
ENHERTU® Showed Substantial Clinical Activity in Patients with …
WEBSep 13, 2024 · Daiichi Sankyo and AstraZeneca’s ENHERTU achieved a 61.6% progression-free survival rate at one year in patients with active or stable brain metastases in DESTINY-Breast12. Largest prospective trial of ENHERTU in this patient population. Tokyo and Basking Ridge, NJ – (September 13, 2024) – Results from the DESTINY-Breast12 phase 3b/4 ...
A New Standard of Care? Enhertu Improves Survival in People …
WEBDec 26, 2022 · Enhertu improves both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer.
Enhertu demonstrated clinically meaningful survival across …
WEBOct 23, 2023 · Results reaffirm potential role of Enhertu as a tumour-agnostic therapy for previously. treated patients with HER2-expressing solid tumours and support ongoing. discussions with global regulatory authorities. Positive results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial …
I’m Embracing Enhertu in 2023 - Curetoday
WEBJanuary 18, 2023. By Elizabeth McSpadden. Article. Last month, I learned that the treatment for my metastatic breast cancer stopped working, but was thrilled to learn about Enhertu — a new drug for a new subset of patients …
Enhertu achieved statistically significant overall survival, reducing ...
WEBDec 7, 2022 · Enhertu showed significant progression-free and overall survival improvements vs. chemotherapy in later-line HER2-positive setting in the DESTINY-Breast02 Phase III trial
ENHERTU® Demonstrated Clinically Meaningful and Durable …
WEBJune 05, 2023. Daiichi Sankyo and AstraZeneca’s ENHERTU showed an objective response rate of 37.1% in the overall population of the DESTINY-PanTumor02 phase 2 trial. ENHERTU is the first therapy to show broad activity across HER2 expressing advanced solid tumors where there are currently no approved HER2 directed therapies.
ENHERTU® Demonstrated Statistically Significant and Clinically ...
WEBApr 29, 2024 · Positive topline results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of care chemotherapy in the primary trial population of …